NIH #5UH3CA207101-05
Colorectal Cancer Molecular Subtype Assay Development and Validation
- Amount
- $150K
- Period
- 2018-09-21 → 2025-08-31
- PIs
- 4
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
Cancer Genomics and Diagnostics · Cancer Research
5 total · 0 active
NIH #5UH3CA207101-05
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5UH3CA207101-04
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #4UH3CA207101-03
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
CSF ctDNA analysis guides molecular reclassification of diffuse glioma patients
Journal of Neuro-Oncology · 2026-05-01
Journal of the American Society of Cytopathology · 2026-05-01
PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma
Clinical Cancer Research · 2026-04-20
Cancer Cytopathology · 2026-03-27
Laboratory Investigation · 2026-03-01
Laboratory Investigation · 2026-03-01
Laboratory Investigation · 2026-03-01
Linking Microbiome Diversity and Immune Profiles in Ethiopian Patients With Cervical Cancer
JCO Global Oncology · 2025-12-01
Cancer Genetics · 2025-12-01
Cancer Genetics · 2025-12-01
Cancers · 2025-10-28 · 4 citations
Molecular Cancer Therapeutics · 2025-10-22
Journal of the American Society of Cytopathology · 2025-09-01
Clinical Lymphoma Myeloma & Leukemia · 2025-08-28
Clinical Lymphoma Myeloma & Leukemia · 2025-08-28
Journal of the National Comprehensive Cancer Network · 2025-05-09 · 4 citations
Cancer Cytopathology · 2025-03-19 · 9 citations
JCO Precision Oncology · 2025-03-01 · 2 citations
Laboratory Investigation · 2025-03-01
106 ESR1 Mutated Advanced Breast Cancer: Clinicopathological and Molecular Characteristics
Laboratory Investigation · 2025-03-01